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ABSTRACT
Despite significant advances in the treatment of hepatitis C virus (HCV) infection, the need to develop preventative vaccines remains.
Identification of the best vaccine candidates and evaluation of their performance in preclinical and clinical developmentwill require
appropriate neutralization assays utilizing diverseHCV isolates.We aimed to generate and characterize a panel ofHCVE1E2 glycopro-
teins suitable for subsequent use in vaccine and therapeutic antibody testing. Full-length E1E2 cloneswere PCRamplified frompa-
tient-derived serum samples, cloned into an expression vector, andused to generate viral pseudoparticles (HCVpp). In addition, some
of these cloneswere used to generate cell culture infectious (HCVcc) clones. The infectivity andneutralization sensitivity of these vi-
ruseswere then determined. Bioinformatic andHCVpp infectivity screening of approximately 900 E1E2 clones resulted in the assem-
bly of a panel of 78 functional E1E2 proteins representing distinctHCVgenotypes anddifferent stages of infection. TheseHCVglyco-
proteins differedmarkedly in their sensitivity to neutralizing antibodies.Weused this panel to predict antibody efficacy against
circulatingHCV strains, highlighting the likely reasonwhy somemonoclonal antibodies failed in previous clinical trials. This study
provides the first objective categorization of cross-genotype patient-derivedHCVE1E2 clones according to their sensitivity to antibody
neutralization. It has shown thatHCV isolates have clearly distinguishable neutralization-sensitive, -resistant, or -intermediate pheno-
types, which are independent of genotype. The panel provides a systematicmeans for characterization of the neutralizing response
elicited by candidate vaccines and for defining the therapeutic potential ofmonoclonal antibodies.
IMPORTANCE
Hepatitis C virus (HCV) has a global burden ofmore than 170million people,many ofwhomcannot attain the new, expensive, direct-
acting antiviral therapies. A safe and effective vaccine that generates bothT cell responses andneutralizing antibodies is required to
eradicate the disease. Regionswithin theHCV surface glycoproteins E1 andE2 are essential for virus entry and are targets for neutraliz-
ing antibodies. Screening of vaccine candidates requires suitable panels of glycoproteins that represent the breadth of neutralization
resistance. Use of a standard reference panel for vaccine studieswill ensure comparability of data sets, as has become routine forHIV-1.
Here, we describe a large panel of patient-derivedHCVglycoproteinswith an assessment of their neutralization sensitivity to defined
monoclonal antibodies, which has enabled us to predict their likely efficacy in thewiderHCV-infected population. The panel could
also be important for future selection of additional therapeutic antibodies and for vaccine design.
The recent development of direct-acting antiviral therapies(DAA) able to potently inhibit hepatitis C virus (HCV) repli-
cation is a major milestone toward limiting the burden of the
disease, but these expensive therapies are likely to remain unat-
tainable by the majority of the 170 million people with persistent
HCV infection. Eradication of the global burden of liver disease
caused by HCV infections will require the introduction of a safe,
effective vaccine. While the immune correlates of vaccine-induced
protection are not completely understood, generation of both ef-
fective T cell responses (1) and neutralizing antibodies (2–7) is
likely to be essential. One of the major challenges in successful
HCV vaccine design is the extreme genetic diversity of HCV pop-
ulations (8), which results from immune-driven adaptation and
escape (9, 10).
The HCV surface glycoproteins E1 and E2 are the major targets
of neutralizing antibodies (reviewed in reference 11). Regions
within these proteins are essential to facilitate interactions with
host cell receptors during entry (12–14). This conservation and
their functional importance make them highly desirable targets
for therapeutic antibodies and vaccines. However, these regions
are thought to be shielded by hypervariable regions, which act as
immunological decoys (15, 16) and are highly glycosylated (17).
Many neutralizing monoclonal antibodies (MAbs) have been
isolated from infected humans (18–22) and experimentally im-
munized animals (23–26). The vast majority of broadly neutraliz-
ing monoclonal antibodies target epitopes that overlap sites in-
volved in the interaction of E2 with host CD81 (21, 27),
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blockading the entry cascade. Antibodies targeting other regions
appear to have restricted reactivity and low neutralizing potency.
An exception to this is the MAb AR4A, which recognizes a con-
served neutralization epitope outside the CD81 binding region
(28).
Experimental HCV glycoprotein vaccines have achieved varied
levels of success (26, 29–32). Similarly, the performance of neu-
tralizing monoclonal antibodies in clinical trials has been ex-
tremely variable (33, 34). Rational screening of lead therapeutic
antibodies and vaccine candidates requires access to suitable pan-
els of viral glycoproteins that represent the breadth of neutraliza-
tion resistance. However, this has been hampered by the limited
number of viruses or glycoproteins available for screening (30,
35). Provision and use of standard reference panels for vaccine
and antibody studies will ensure comparability of data sets, as has
become routine practice for HIV-1 (36). This will ensure that
efforts can be focused on the most promising candidates and will
prevent advancement of vaccines and treatments that have a high
risk of failing against viruses circulating in HCV-infected popula-
tions.
Here, we describe the generation of a large panel of patient-
derived HCV envelope glycoproteins from individuals at dif-
ferent stages of disease and infected with different genotypes,
together with an assessment of their relative infectivities and
neutralization sensitivity to defined monoclonal antibodies,
which has enabled us to predict their likely efficacy in the wider
HCV-infected population. The panel will also be important for
future selection of additional therapeutic antibodies and for
vaccine design (36).
MATERIALS AND METHODS
Glycoprotein cloning and phylogenetic analysis. cDNA sequences en-
coding full-length E1E2 were amplified from RNA extracted from patient
sera and cloned into the pcDNA3.1 V5his D-TOPO expression vector
(Life Technologies), as previously described (37). As controls, the E1E2
genes from the widely used HCV strains H77, JFH1, and J6 were cloned
into the same vector. Nucleotide sequences were determined by Sanger
sequencing and aligned using Clustal W. Phylogenetic relationships were
determined using maximum-likelihood analyses, as previously described
(10). Bootstrap analysis with 500 replicates was performed to provide
statistical support to the sequence clusters.
Cell lines. The human embryonic kidney 293T and Huh-7 human
hepatoma cell lines were purchased from ECACC, and the Huh-7.5 cell
line was obtained from Apath, LLC. All were grown in Dulbecco’s
modified essential medium (DMEM) (Invitrogen) supplemented with
10% fetal bovine serum (FBS) and 0.1 mM nonessential amino acids
(Invitrogen).
Antibodies. Anti-E2 MAbs 1:7, L1, XTLAb68, and AP33 have been
previously described (23, 34, 38), as has the anti-E2 nanobody (nB) D03
(26).
HCVpp generation and infectivity and neutralization assays.
Cloned E1E2 genes were used to generate HCV pseudoparticles (HCVpp),
essentially as described previously (37). Pseudoparticles generated in the
absence of the E1E2 plasmid were used as a negative control. Core expres-
sion, for a subset of HCVpp production runs, was analyzed by Western
blotting (35), and there were no discernible differences in expression lev-
els (not shown). Infectivity assays were conducted as previously described
(35). For neutralization assays, pseudotype virus was mixed with defined
concentrations of antibody, incubated for 1 h at 37°C, and then added to
Huh-7 cells. Cultures were incubated and read as for the infectivity assay.
All assays were done in triplicate. The 50% inhibitory concentration
(IC50) titer was calculated as the MAb concentration that caused a 50%
reduction in relative light units (RLU) compared to the level in the virus
control wells after subtraction of cell control RLU. All the data were fitted
using nonlinear regression plots with no constraint on the Hill slope
(GraphPad Prism version 6.05).
HCVcc generation and neutralization assay. Genotype 2 (Gt2) cell-
culture-infectious (HCVcc) clones were generated essentially as described
previously, using restriction digest cloning and PCR (39). Neutralization
assays were performed as previously described (26). The percent infection
was determined by comparison to the number of cells infected in the
absence of inhibitors, as determined by NS5A staining with MAb 9E10
(40).
Statistical analysis. Viruses were compared with respect to overall
neutralization sensitivity by rank ordering based on mean log10 IC50
titers across the five antibodies. A heat map describing the clustering
patterns was generated using the heat map tool of the Los Alamos
database (http://www.hiv.lanl.gov/content/sequence/HEATMAP/
heatmap.html). The robustness of membership within a given cluster
was evaluated by bootstrap resampling of the data. Frequency distri-
bution plots fit a normal distribution curve, as shown by the
D’Agostino and Pearson omnibus normality test (GraphPad Prism
version 6.0). Highlighter plots were generated using the tool in the
Los Alamos database (http://www.hiv.lanl.gov/content/sequence
/HIGHLIGHT/highlighter_top.html).
Nucleotide sequence accession numbers. The E1E2 sequences de-
scribed in this study have been deposited in GenBank under accession
numbers KU285151 to KU285228.
RESULTS
Production of the HCV E1E2 glycoprotein panel. A total of 883
E1E2 clones were generated from 3,909 patients enrolled in the
Trent HCV cohort. Of these, 493 clones from 63 different sub-
jects were sequenced and identified as containing complete
E1E2 open reading frames. These were then screened for infec-
tivity using a murine leukemia virus (MLV)-based pseudopar-
ticle assay. One hundred eighteen clones were classified as in-
fectious (yielding a relative luminescence value at least 10-fold
greater than background). Of these, 78 clones from 36 different
patients were selected for use in the neutralization panel, of
which 5 (14%) were sampled during the acute early phase and
31 during chronic infection (86%) (Table 1). In addition, the
standard reference strains H77, JFH-1, and J6 were included.
The clones were chosen to ensure that they represented the
major HCV genotypes (Fig. 1A) and a range of infectivities
(Fig. 1B), although glycoproteins that conferred very low levels
of infectivity were omitted from subsequent analyses because
of unacceptably high intra- and interassay variability com-
pared to an isolate with higher infectivity. Invariably, these
low-infectivity clones were relatively easy to neutralize and
therefore deemed less clinically relevant than neutralization-
resistant strains.
Estimated inhibitory concentrations of antibody are consis-
tent between experimental runs. Due to the large number of
clones included in the neutralization assays and the inherent vari-
ability of RLU values that could be observed between experimen-
tal runs, we compared IC50s between two independent neutraliza-
tion assays to allow us to evaluate interassay reproducibility.
HCVpp supplemented with six clones previously shown to ex-
hibit different neutralization resistance phenotypes were tested
in two separate neutralization assays using the same CD81
binding site MAbs that were to be used for the subsequent
analyses of the full panel. There was good correlation between
the two different runs for all of the antibodies tested (Fig. 2),
irrespective of the genotype or the magnitude of the IC50. These
HCVpp Panel Has Differential Neutralization by MAbs
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FIG 1 E1E2 glycoprotein clones, representing the major HCV genotypes, show varying degrees of infectivity. Shown are maximum-likelihood phylogenetic
analysis (A) and relative infectivity (B) of the 81 E1E2 clones used for the antibody neutralization panel. (A) The genetic distance for each of the branch lengths
shown in the phylogenetic tree is indicated by the scale bar, and the level of bootstrap support (for those branches supported by95% of replicates) is indicated
above each branch. (B) HCVpp generated without a glycoprotein envelope reproducibly gave RLU values of less than 20, and therefore, a cutoff 200 was used to
determine if the clone was infectious; only those clones defined as infectious are shown. The data are mean values of triplicates  standard deviations (SD).
UKNP, United Kingdom Nottingham Panel, followed by the genotype, patient number, and isolate number.
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FIG 2 The estimated inhibitory concentrations of antibodies are consistent between different neutralization assay runs. IC50s for MAb AP33, MAb 1:7,
MAb L1, nAb D03, and XTL68, estimated from two independent neutralization assays using HCVpp supplemented with E1E2 proteins representing the
six major genotypes, were compared to assess the impact of interassay variability. The IC50 titer for each repeat assay was plotted for the entire data set (All
IC50s) or for each of the 6 HCVpp. The solid lines show the best fit of the experimental data. Pearson correlation coefficient R values are shown, along with
the associated P values.
TABLE 1 Numbers of clones analyzed from each of the six major HCV genotypes
Genotype
Total no.
of clones
isolated
No. of
clones
screeneda
No. infectious
clonesa
No. of infectious
clones in the
panela
Gt1 504 280 (32) 92 (23) 58 (23)
Gt2 85 19 (9) 8 (5) 6 (5)
Gt3 184 130 (12) 7 (3) 5 (2)
Gt4 35 19 (3) 6 (3) 5 (3)
Gt5 51 36 (6) 3 (2) 2 (2)
Gt6 24 9 (1) 2 (1) 2 (1)
Total 883 493 (63) 118 (37) 78 (36)
a Total number (number of unique subjects).
HCVpp Panel Has Differential Neutralization by MAbs
April 2016 Volume 90 Number 7 jvi.asm.org 3291Journal of Virology
 o
n
 June 17, 2016 by Univ of Nottingham
http://jvi.asm.org/
D
ow
nloaded from
 
results show that our experimental approach was subject to low
run-to-run variability.
Patient-derived glycoprotein clones of the same subtype can
differ markedly in their sensitivity to neutralization. From the
larger panel of 81 infectious clones, a subset of 5 genotype 1 clones,
together with the reference molecular clone H77, were tested
against four MAbs (AP33 [41], 1:7 [38], L1 [38], and XTL68 [34])
and one nanobody (nB D03 [26]), all of which target discrete
epitopes located in the CD81 binding site. The IC50s are presented
in Table 2, and the corresponding neutralization curves are pre-
sented in Fig. 3. Sensitivity to neutralization varied across the six
genotype 1 isolates, with some being highly sensitive to the anti-
bodies (e.g., UKNP1.2.3) while others were highly resistant (e.g.,
UKNP1.10.1). These data strongly support the view that sensitiv-
ity to a neutralizing antibody is determined at the isolate rather
than the genotype level.
Extensive variability in neutralization sensitivity of patient-
derived envelope glycoproteins. Neutralization assays were per-
formed to determine the sensitivity of each of the 81 clones in the
larger glycoprotein panel to neutralization by each of the five an-
tibodies, and the means of the resulting IC50s for E1E2 HCVpp
clones were calculated and plotted, together with their ranges, in
mean rank order (Fig. 4). These mean IC50s constituted a spec-
trum. The inset shows that when the isolates are split into chronic
and acute early phase samples, there is no significant difference in
the log10 IC50s between the groups. The most easily neutralized
E1E2 clone (UKNP1.21.2) had a mean IC50 of 0.013 g ml
1,
whereas the most resistant clone (UKNP2.4.1) had a mean IC50 of
49 g ml1. When the neutralization sensitivities of the clones
were analyzed according to individual antibodies (Fig. 5), their
relative positions in the neutralization spectrum were on the
whole maintained, indicating an inherent sensitivity to neutraliza-
tion by CD81 binding site-targeting antibodies. However, a few
clones had greater sensitivity to some antibodies than their relative
positions in the plot of mean IC50s would suggest. For example,
UKNP1.16.2 was very susceptible to neutralization by MAb L1
TABLE 2 IC50s of neutralization curves in Fig. 3
Clone
IC50 (g ml
1)a
MAb AP33 MAb 1:7 MAb L1 nB D03 MAb XTL68
H77.20 0.1012 0.5388 2.031 9.167 0.6316
UKNP1.2.3 0.01467 0.009883 0.03123 0.02079 0.03315
UKNP1.3.2 0.1294 0.0553 0.06801 0.1913 0.05287
UKNP1.4.1 0.2245 0.8219 0.1371 0.2545 1.27
UKNP1.10.1 2.118 11.88 15.47 5.091 44.02
UKNP1.11.7 0.1408 0.1022 0.99 0.3288 0.1833
a The IC50 for each genotype 1 HCVpp/antibody curve was calculated using nonlinear regression plots with no constraint on the Hill slope (GraphPad Prism version 6.05).
FIG 3 Genotype 1 clones show both resistant and sensitive phenotypes. HCVpp supplemented with genotype 1 E1E2 proteins H77.20, UKNP1.2.3, UKNP1.3.2,
UKNP1.4.1, UKNP1.10.1, and UKNP1.11.7 were neutralized by increasing concentrations of MAb AP33, MAb 1:7, MAb L1, nB D03, and MAb XTL68, and the
resulting infectivity was plotted against the antibody concentration.
Urbanowicz et al.
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(Fig. 5), while UKNP1.12.1 was very susceptible to neutralization
by MAb XTL68 (Fig. 5). No neutralization was observed when
antibodies were tested against a negative control (vesicular stoma-
titis virus G [VSV-G]) or when pseudoparticles were assayed using
anti-tetanus toxin MAb (Wyeth) (data not shown). The mean
IC50s (standard deviations) for MAbs AP33, 1:7, L1, D03, and
XTL68 were 0.6872 (1.587), 2.105 (5.909), 4.581 (14.59),
2.289 (4.600), and 8.887 (24.69) g ml1, respectively.
The neutralization phenotypes of patient E1E2 proteins are
consistent in both HCVpp and HCVcc models of infection. To
determine if the same pattern of neutralization sensitivity also
applied to the cell culture model, two Gt2 E1E2 clones from the
panel were transferred into the J6/JFH-1 cell-culture-infectious
HCV backbone (Fig. 4, arrows). These clones and three reference
strains, JFH-1, J6/JFH-1, and H77/JFH-1, represented a breadth of
neutralization sensitivities, as predicted from the HCVpp panel,
and were tested against MAb 1:7 (Fig. 6, left, and Table 3). Even
with this small subset, there was a significant correlation (r 
0.8938; P  0.0152) between the neutralization data obtained in
the HCVpp and HCVcc systems (Fig. 6, right).
Increased infectivity conferred by E1E2 clones is associated
with increased neutralization resistance. To investigate the re-
lationship between infectivity and neutralization sensitivity,
the mean log10 IC50s were plotted against the relative infectivity
(as defined by the RLU value) of each of the E1E2 clones (Fig.
7). There was a direct correlation between increased neutral-
ization resistance, as indicated by increasing IC50s, and in-
creased infectivity, and this correlation was statistically signif-
icant (r 0.8513; P 0.0001). This trend was also maintained
when the analysis was performed using individual MAb IC50
data (not shown). E1E2 clone UKNP2.4.1 had the highest level
of infectivity, and it was also the most resistant to antibody
neutralization.
The glycoprotein panel can be used to predict the likely effi-
cacy ofmonoclonal antibodies against circulatingHCV strains.
An important aim of this study was to determine whether the
glycoprotein panel could be used to inform future vaccine and
therapeutic antibody efficacy by predicting likely neutralizing
potencies against a wider set of patient-derived isolates. Plots
of log10 IC50s for each antibody showed a normal distribution
(Fig. 8), meaning that each antibody plot could be used to
predict an antibody concentration that would exceed the IC50
for 95% (equal to the mean of the neutralization distribution
plus 2 standard deviations) or 99% (mean plus 3 standard de-
viations) of HCV isolates (Table 4). For MAb AP33, a concen-
tration of 8 g ml1 would be sufficient to meet the IC50s of
95% of circulating HCV strains, but this would need to be
increased to 59 g ml1 in order to effectively neutralize 99%
of circulating isolates. In comparison, concentrations of
XTL68 of 117 g ml1 and 1.51 mg ml1 would be needed to
provide the same level of neutralization for 95% and 99% of
circulating HCV isolates, respectively.
Patient-isolated E1E2 can be categorized into distinct neu-
tralization phenotype clusters. In order to categorize the E1E2
panel into groups based on similar neutralization phenotypes, we
next performed hierarchical cluster analysis of the IC50 titers for
FIG4 Pseudotype viruses incorporating different E1E2 clones derived from the major HCV genotypes display diverse susceptibilities to antibody neutralization.
Eighty-one distinct patient-derived and reference E1E2 clones were assessed for neutralization sensitivities using five monoclonal antibodies. The mean log10 IC50
neutralization value, and the range, for each HCVpp supplemented with E1E2 derived from genotypes 1, 2, 3, 4, 5, and 6 were plotted in rank order from lowest
(most sensitive) to highest (least sensitive). The arrows indicate the clones that were used in the subsequent HCVcc analysis. The inset graph shows the mean
neutralization IC50s for E1E2 genes sampled from either acute or chronic HCV infection. Both groups possessed similar neutralization resistance phenotypes, as
shown by a one-way analysis of variance.
HCVpp Panel Has Differential Neutralization by MAbs
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FIG5 Pseudotype viruses incorporating different E1E2 clones derived from the major HCV genotypes display diverse susceptibilities to antibody neutralization.
Eighty-one distinct patient-derived and reference E1E2 clones derived from genotypes 1, 2, 3, 4, 5, and 6 were assessed for their neutralization sensitivity to five
monoclonal antibodies. The log10 IC50 for MAbs AP33, 1:7, L1, and XTL68 and nB D03 are plotted according to the E1E2 clone’s rank order presented in Fig. 4.
Urbanowicz et al.
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each isolate/MAb. The E1E2 clones segregated into three distinct
groups (Fig. 9). One group consisted of 16 E1E2 clones that were
highly resistant to neutralization (blue box), one consisted of 14
highly sensitive E1E2 isolates (black box), and the third group
consisted of isolates with an intermediate phenotype. Each cluster
contained a mixture of different genotypes, once again highlight-
ing the fact that the genotype has little, if any, bearing on sensitiv-
ity to neutralization. The mean (standard deviation) of IC50s
observed for the resistant cluster was 15.9 (14.74)g ml1 com-
pared to 0.05468 (0.03714) g ml1 for the group of sensitive
viruses. This highlighted the extreme differences in inherent neu-
tralization sensitivity between patient-derived isolates. Analyzed
separately, the mean IC50s for each antibody also showed large
differences between the two groups (Table 5). To establish if there
were any common amino acids in the E1E2 genes that conferred
the resistant or sensitive phenotype, highlighter analysis was per-
formed to identify matches with a selected resistant (UKNP1.6.1)
and sensitive (UKNP1.2.3) clone. However, no common amino
acid predicted either of the two phenotypes (Fig. 10), suggesting
that neutralization resistance can occur through multiple mecha-
nisms.
DISCUSSION
Future HCV vaccines or antibody-based therapies will need to be
effective against the majority, if not all, of the viruses present in
infected individuals. This requires good preclinical screening of
interventions to identify the best leads, which in turn relies upon
the availability of reference panels of patient-derived HCV iso-
lates. While some groups have reported successful culture of pa-
tient-derived HCV, these methods generally exhibit poor replica-
tion efficiency and therefore do not represent a tractable means of
predicting neutralization sensitivity in vivo; instead, surrogate
models, such as the HCVpp system or chimeric HCVcc, have
proven to be more robust tools (reviewed in reference 42). Previ-
ous studies on antibody neutralization have used the cell line
Huh7.5 (40) or primary hepatocytes (43); we chose the former, as
that cell line is more amenable and the HCV entry process is com-
parable to that observed in primary hepatocytes (44–46).
We had previously shown that patient-derived E1E2 clones
were differentially susceptible to neutralization by human poly-
clonal sera, and this appeared to be unrelated to the genotype (35).
Here, we extend those preliminary studies by generating a signif-
icantly larger panel of E1E2 HCVpp clones, drawn from different
genotypes that are representative of individuals at different stages
of infection. This marks a major advancement in the field, where
existing knowledge of protective antibody determinants has been
derived from much smaller or genotype-restricted HCVpp or
HCVcc panels (28, 39, 47, 48). Importantly, our data highlight the
fact that intra- or intergenotypic differences do not noticeably
impact sensitivity to neutralization (at least not with respect to
CD81 binding site-targeting MAbs) and that this property is de-
termined at the isolate level. In our initial screening, we identified
a number of clones that were not functional in the HCVpp system.
This has been observed previously (12), and the reasons for this
lack of functionality remain unclear.
One of the most striking observations was the extreme variabil-
ity in neutralization sensitivity that patient-derived E1E2 clones
demonstrated. While many E1E2 clones showed similar degrees of
sensitivity to CD81 binding site-targeting MAbs, there were a
number of isolates that were especially sensitive or resistant. Com-
parisons between resistant and sensitive strains failed to identify
common sequence substitutions or motifs giving rise to this dif-
ference. Identifying mechanisms of resistance will be important in
understanding neutralizing antibody responses, although it is
likely that sequence differences underlying these different neutral-
ization phenotypes will be highly isolate specific.
While our panel contained predominantly subtype 1a and
TABLE 3 Comparison of neutralization IC50s of patient-isolated clones
in both the HCVpp and HCVcc infection models
HCVcc clone Neutralization ranka
IC50 (g ml
1)
HCVpp 1:7 HCVcc 1:7
JFH-1 32 0.06 2.37
H77.20 60 0.55 3.51
UKNP2.5.1 65 1.47 6.25
J6 71 0.82 8.41
UKNP2.4.1 81 19.11 21.05
a Position in the ranking of the mean IC50 HCVpp neutralization values presented in
Fig. 4.
FIG 6 A subset of E1E2 clones transferred to a chimeric HCVcc infection model has neutralization sensitivity concordant with that in the HCVpp model. (Left)
Two E1E2 clones showing high resistance in the HCVpp panel were transferred into the J6/JFH-1 backbone and neutralized, along with J6, JFH-1, and H77, with
increasing concentrations of MAb 1:7. The error bars indicate SD. (Right) The IC50s for both the HCVcc and HCVpp showed significant correlation (r 0.8938;
P 0.0152).
HCVpp Panel Has Differential Neutralization by MAbs
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1b viruses, there was a sufficiently large number of clones rep-
resenting the other major genotypes to be confident that the
panel could provide a robust prediction of the neutralizing
potency of individual MAbs against HCV strains present in
infected individuals. For example, the panel has enabled us to
estimate that 8 g ml1 of MAb AP33, which equals the mean
IC50 plus 2 standard deviations, will provide at least 50% neu-
tralization for 95% of patient-derived isolates, whereas for
XTL68, this would increase to 117 g ml1. Importantly, this
type of screening strategy provides insight into the likely po-
tency of any given MAb when used against any patient-derived
isolate. Given the observed correlation between in vitro and in
vivo anti-HCV activities of MAbs (49, 50), this approach could
be used to provide a quick indication of an antibody’s potential
clinical value. In this respect, it is important to note that in a
previous clinical trial, MAb XTL68 had only modest effect
when administered to HCV-infected individuals (34). It is also
important to note that other factors, such as the potential for
MAb-driven escape (51), are also important parameters in de-
termining the likely clinical value of any particular antibody or
antibody combination. Finally, resistance to MAb neutraliza-
tion was correlated with the degree of infectivity, as determined
by the HCVpp assay. Such a relationship between increased
antibody neutralization resistance and improved HCVpp in-
fectivity has been reported previously in analyses of polyclonal
sera obtained from a small cohort of liver transplant recipients
(43).
Having established that isolates showed a wide range of neu-
tralization sensitivities, we performed cluster analysis to define
clusters of MAb sensitivity. The bulk of isolates showed variable
patterns of neutralization— easily neutralized by some but not all
MAbs tested. However, there were two distinct clusters that rep-
resented the two extremes, one highly sensitive and one highly
resistant group. Both clusters contained viruses drawn from
highly divergent genotypes. The mean IC50, for all five antibodies,
of the resistant group was 290 times greater than that observed for
the sensitive group. This was also true for the antibodies individ-
ually. The resistant viruses pose a major challenge for vaccine de-
velopment and cannot be ignored; otherwise, deployment of a less
than optimal vaccine would result in the selection and eventual
dissemination of a virus population refractive to neutralization, as
has been observed in the most promising HIV-1 vaccine trial to
date (52).
Importantly, two strains (H77c and JFH-1) that have been
used extensively to test the potency of candidate vaccine-induced
sera fall outside the neutralization-resistant cluster. In contrast,
the J6 reference strain is a more relevant reference strain to include
in this type of analysis, which probably explains the variable neu-
tralization observed for E1E2-elicited immune sera (29). This is
consistent with the antibody neutralization resistance of this clone
that was evident, but not commented upon, in previous studies
(29, 53).
HCVpp represents a rapid, amenable way to test antibody
neutralization against a large number of different isolates. Im-
portantly, we have shown, at least for a subset of isolates, that
the HCVpp-derived neutralization data accords with those ob-
tained using chimeric HCVcc. While significant advances have
been made in generating more diverse panels of infectious vi-
rus, it is still a very laborious process, so the range of isolates
available is still very limited (28, 39). Although the HCVpp
system provides greater flexibility with respect to the number
of HCV isolates that can be tested easily, our data show that
while there was good correlation between the two systems,
HCVpp were more easily neutralized than the corresponding
HCVcc chimeras. Therefore, while HCVpp is an easy system
for rapid screening of MAbs and sera, the findings would need
to be validated in the HCVcc system. Also, HCVcc chimeras
utilizing more clinically relevant isolates are required for in
vivo studies. Therefore, creation of chimeras of the clones rep-
resenting resistant-cluster isolates is under way.
Our study focused on an initial characterization of the panel,
using MAbs that targeted the CD81 binding site. These MAbs
represent the majority of murine and human cross-neutralizing
anti-HCV MAbs. Differences in sensitivity to antibodies and poly-
clonal sera targeting other neutralizing determinants will be im-
portant to assess in the future. However, it is important to reiterate
FIG7 HCVpp infectivity conferred by E1E2 clones is correlated with its resistance to antibody neutralization. The mean uninhibited infectivity (RLU value), and
the range, for each of the 81 E1E2 clones supplementing HCVpp was plotted against the mean log10 IC50 neutralization titer. r 0.8513; P 0.0001.
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that in our previous analysis of a much smaller panel using poly-
clonal sera, a similar spectrum of neutralization was observed
(35).
In conclusion, this study provides the first objective categori-
zation of cross-genotype patient-derived HCV E1E2 clones ac-
cording to their sensitivity to antibody neutralization and showed
that individual HCV isolates can be categorized as having a clearly
distinguishable neutralization-sensitive, -resistant, or -intermedi-
ate phenotype. We were able to use the panel to predict the likely
efficacies of a number of CD81 binding site MAbs against circu-
lating HCV strains. This reference panel will be indispensable for
future studies of the therapeutic potential of existing and newly
FIG 8 Normally distributed IC50s for each antibody. Shown are frequency distribution plots of log10 IC50s, and the derived Gaussian curves, from all 81 clones
for MAbs AP33, 1:7, L1, and XTL68 and nB D03. The mean log10 IC50 for each antibody is represented by a red dashed line, the mean 2 standard deviations
by solid red lines, and the mean  3 standard deviations by gray shading. Each plot fit a normal distribution curve, as shown by the D’Agostino and Pearson
omnibus normality test.
TABLE 4 IC50s from frequency distribution plots in Fig. 5
Antibody
IC50 (g ml
1)a
95% HCV isolates 99% HCV isolates
AP33 8 59
1:7 22 196
L1 54 662
D03 32 293
XTL68 117 1,517
a IC50s were estimated from the frequency distribution plots based on the mean values
plus 2 standard deviations (95%) or mean values plus 3 standard deviations (99%).
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FIG 9 In hierarchical cluster analysis, the E1E2 clones can be grouped according to their sensitivity to monoclonal antibody neutralization. HCV E1E2 pseudoviruses
(n 81) were assessed for neutralization sensitivities using five MAbs targeting discrete epitopes of the CD81 binding site. Individual clones are listed on the right, and
antibodies are indicated at the base of the heat map. The magnitude of neutralization (log10 IC50 titer) is denoted by the color, where higher values of neutralization are
represented by lighter colors (e.g., light yellows) and lower values are represented by more saturated, dark colors (e.g., dark red). Boxes are drawnaround viral isolates that
were resistant (blue) and sensitive (black) to neutralization that grouped with90% probability according to bootstrap resampling (10,000 replicates) of the data set.
TABLE 5 Mean IC50s for the resistant and sensitive neutralization clusters for all antibodies and individual antibodies
a
Cluster
Mean IC50 (g ml
1)
Combined AP33 1:7 L1 D03 XTL68
Sensitive 0.05468 (0.03714) 0.0136 (0.01475) 0.06553 (0.07598) 0.0675 (0.1175) 0.02213 (0.0177) 0.1046 (0.1257)
Resistant 15.9 (14.74) 2.541 (2.903) 8.545 (11.11) 20.39 (28.23) 7.501 (7.053) 40.52 (43.51)
a Numbers in parentheses are standard deviations of the means.
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discovered MAbs, used alone or in combination, as well as the
potency of immune-generated sera.
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